2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.

Lambein, Kathleen;Van Bockstal, Mieke;Denys, Hannelore;Libbrecht, Louis
(2014) Journal of Clinical Oncology — Vol. 32, n° 17, p. 1856-1857 (2014)

Files

2014_Lambein_J_Clin_Oncol.pdf
  • Restricted Access
  • Adobe PDF
  • 58.05 KB
Request a copy

Details

Authors
  • Lambein, Kathleen
    Author
  • Van Bockstal, Miekeorcid-logoUCLouvain
    Author
  • Denys, Hannelore
    Author
  • Libbrecht, LouisUCLouvain
    Author
Abstract
(en) TO THE EDITOR: The 2013 update of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer reverts to the US Food and Drug Administration criterion regarding the definition of immunohistochemistry (IHC) -positive breast cancer. [...]
Affiliations
  • Ghent University HospitalDepartment of Pathology

Citations

  • APA
  • Chicago
  • FWB

Lambein, K., Van Bockstal, M., Denys, H., & Libbrecht, L. (2014). 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. Journal of Clinical Oncology, 32(17), 1856-1857. https://doi.org/10.1200/JCO.2013.54.2530 (Original work published 2014)